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Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cyto-
megalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as
well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement
was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates.
Analysis of these results indicates the problems associated with clinical isolates, including the large genetic
variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems,
represents a significant step toward the development of a standardized assay.
Cytomegalovirus (CMV) is a major opportunistic pathogen
in immunocompromised hosts. Long-term therapy with ganci-
clovir (GCV) and foscarnet (PFA) has been associated with
development of clinical resistance and progression of disease
(3, 4, 9, 10). Standardized laboratory methods to rapidly and
accurately determine the susceptibility of CMV isolates to an-
tiviral drugs are needed. The inherent difficulties in working
with CMV include the slow growth of the virus and the fact
that CMV clinical isolates are strongly cell associated. Multiple
passages in culture are typically required to generate sufficient
extracellular virus for titration and testing. Standard suscepti-
bility assays require the inhibition of viral replication in the
presence of serial concentrations of drug. The slow growth of
CMV has limited the usefulness of standard assays in patient
management and in guiding clinical trials. Thus, the ultimate
goal is to develop a rapid method that can be used directly on
clinical samples to detect resistance mutations (1, 11). As a first
step toward this goal, 12 laboratories in the CMV Resistance
Working Group of the AIDS Clinical Trials Group (ACTG)
have collaborated in formulating and testing a standardized
plaque reduction assay to use as a “gold standard.” In the first
phase of this process, four characterized plaque-purified CMV
strains (two laboratory strains and two clinical isolates) were
distributed and tested in 12 laboratories using variations of a
plaque reduction assay. In the second phase, a consensus assay
was used to retest these strains, as well as six additional coded
clinical isolates. The inhibition curves were calculated by com-
puter modeling using a PROC NLIN program of SAS. The
results are presented in this report.
MATERIALS AND METHODS
Cells and drugs. In phase 1, human diploid fibroblasts from a variety of
sources, commercial and in-house, were used. In phase 2, MRHF (human fore-
skin) cell cultures (Biowhittaker, Walkersville, Md.) were used by all of the
laboratories. GCV was provided by Syntex-Roche, and PFA was provided by
Astra Pharmaceuticals. The drugs were prepared from common lots by the Viral
Quality Assurance Laboratory of the ACTG at Rush-Presbyterian-St. Luke’s
Medical Center. GCV (4.5 mM) and PFA (20 mM) stocks were filter sterilized,
shipped on dry ice to participating laboratories, and kept at 270°C until they
were used. At the time of overlay preparation, the drugs were thawed in a 37°C
water bath with intermittent shaking to ensure complete dissolution.
Virus strains. CMV strain AD169 and a laboratory-generated GCV-resistant
mutant, XbaF, with a deletion in the UL97 gene (12), were plaque purified and
provided by Karen Biron and Sylvia Stanat of Burroughs Wellcome Co. (Re-
search Triangle Park, N.C.). A GCV-sensitive pretreatment (C9208) and GCV-
resistant late-treatment (C9209) pair of clinical isolates were provided by Alejo
Erice (University of Minnesota) (1); both were plaque purified three times prior
to distribution. In phase 2, in addition to the above CMV strains, six recent
clinical isolates (5, 7) were provided by Richard Miner and W. Lawrence Drew
(Mt. Zion Hospital, San Francisco, Calif.) and Alejo Erice to the ACTG Viral
Quality Assurance Laboratory, where they were grown, aliquoted and shipped
under code names (CMV 1 to 6) on dry ice to participating laboratories. Clinical
information, responses to therapy, original susceptibility test results, and muta-
tion analyses for the eight clinical isolates are presented in Table 1.
Virus stock preparation and titration. Cell-free virus stocks (AD169 and
XbaF) were titered by serial 10-fold dilution in tissue culture plates containing
human fibroblast monolayers overlaid with agarose. After incubation for 7 to 10
days, the cultures were fixed and plaques were enumerated. PFU per milliliter
were determined. The other CMV strains tested were cell-associated clinical
isolates. For these, the virus was quantitated by estimating the number of plaque-
forming cells (PFC) present in an infected culture (11). When viral cytopathic
effects (CPE) involved approximately 70 to 80% of the monolayer, the cells were
trypsinized and resuspended in minimal essential medium (MEM) with 8 to 10%
fetal bovine serum (FBS), and an aliquot was counted in a hemacytometer. The
number of PFC was then determined by multiplying the number of cells in the
suspension by the percentage estimated to be infected, as evidenced by CPE. For
the consensus assay, the cell concentration was adjusted to 400 PFC/ml in 2%
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MEM to provide an inoculum dose of 60 to 80 PFC/0.2 ml. The plates were
inoculated on the same day when possible. Alternatively, the infected cell sus-
pension was centrifuged at low speed (250 3 g for 10 min) and the cell pellet was
resuspended in cryoprotective medium (20% FBS–10% dimethyl sulfoxide–
MEM). The cell suspensions were frozen slowly at a titer of 4 3 105 PFC/ml and
stored at 280°C until use, when they were thawed quickly and diluted in MEM
with 2% FBS to obtain a concentration of 400 PFC/ml.
Consensus plaque reduction assay. In phase 1, several variations of a plaque
reduction assay were used (3, 4, 11). In phase 2, the consensus assay described
below was used by all of the laboratories. The consensus plaque reduction assay
was the result of modifications following the first phase of the study.
MRHF cells, used at population-doubling levels of 26 to 30, in 24-well plates
were inoculated when the cells were just confluent. Each well was inoculated with
0.2 ml of virus suspension containing 40 to 80 PFC of cell-associated virus. For
cell-associated viruses, the medium was not aspirated prior to inoculation. After
adsorption for 90 min at 37°C, the medium was carefully aspirated and the wells
were overlaid with 1.5 ml of 0.4% agarose containing the appropriate concen-
tration of the antiviral drug; three wells were used per drug concentration. For
the overlay, a 0.8% stock of SeaPlaque agarose (FMC Bioproducts, Rockland,
Maine) was mixed with an equal volume of 23 concentrations of drug in 23
MEM with 10% FBS and antibiotics. The following final drug concentrations
were used in the consensus assay: GCV, 0, 1.5, 3, 6, 12, 24, 48, and 96 mM, and
PFA, 0, 25, 50, 100, 200, 400, 800, and 1,600 mM. The final concentration of the
overlay was 0.4% agarose in MEM with 5% FBS. The plates were incubated for
7 days at 37°C in a 5% CO2 incubator or until there were at least 40 plaques in
the control wells. Monolayers were fixed in 10% formalin in phosphate-buffered
saline and then stained with 0.8% crystal violet in 50% ethanol. The plaques were
counted microscopically at low power.
Statistical methods. Resistance was assessed by calculating a 50% inhibitory
concentration (IC50) for each assay in each laboratory. First, plaque ratios were
formed by dividing the plaque counts at the positive drug doses in an assay by the
mean of the plaque counts for the three controls in the same assay. The IC50 for
each assay was then estimated from the set of ratios by fitting the median effect
equation (2): R 5 1/1 1 (IC50/d)m where d is the drug dose (d . 0), IC50 is the
50% infectious dose, and m is a parameter. Curve fitting was done by the PROC
NLIN program of SAS. A few values of R were greater than 1.0, but no adjust-
ment was made for these in the analysis. Values above 1.0 occurred mainly at the
lowest doses of each drug. IC50s were not calculated for assays that did not reach
endpoints. An assay was considered to have failed to reach an endpoint if R was
.0.50 for all replicates at all drug concentrations. In this case, the IC50 was
defined to be greater than the maximum dose used in the assay. The minimum,
median, and maximum IC50s across the 12 laboratories were calculated for each
strain exposed to each drug. Robust standard deviations were also calculated
from the 25th and 75th percentiles (Q1 and Q3, respectively) of the IC50s for
each combination of strain and drug. Assuming that the IC50s are normally
distributed, the standard deviation is approximately (Q3 2 Q1)/1.33. A standard
deviation was not calculated if Q3 was greater than the maximum dose of drug
in the assay.
Definition of sensitive and resistant IC50s. Sensitive, indeterminate, and re-
sistant ranges for GCV and PFA were tentatively adopted from previous work as
follows: for GCV, an IC50 of #6 mM was considered sensitive, .6 to 12 mM was
considered indeterminate, and .12 mM was considered resistant; for PFA, an
IC50 of ,400 mM was considered sensitive and $400 mM was considered resis-
tant (3, 8, 11). There was no indeterminate range for PFA.
RESULTS
Comparison of initial and ACTG consensus plaque reduc-
tion assays using plaque-purified viruses. In phase 1, several
different plaque reduction assays were used by participating
laboratories. In phase 2, only the consensus assay was used. In
both phases, two cell-free CMV laboratory strains (AD169 and
XbaF) and two cell-associated clinical isolates (C9208 and
C9209) were tested against both GCV (Table 2) and PFA
(Table 3). For a valid comparison, the results were included
only when laboratories submitted results for a given CMV
strain in both phases 1 and 2 of the study. When more than one
result was provided, only the first was used for this comparison.
In some cases, indicated in the table as not available (NA),
the software for estimating IC50 failed to converge to a solu-
tion.
(i) GCV results. For GCV, the number of laboratories suc-
cessfully completing assays for the cell-free laboratory strains
(AD169 and XbaF) was greater than the number completing
results for the cell-associated clinical isolates (C9208 and
C9209). The coefficient of variation (CV) was similar in both
phases for the cell-free laboratory strains and was not consis-
tently lower with the ACTG consensus assay for the clinical
isolates (Table 2).
The majority of the laboratories successfully distinguished
sensitive (AD169 and C9208) and resistant (XbaF and C9209)
strains. However, some results in both phases 1 and 2 did not
fall into the anticipated range. For AD169, two results in phase
1 and three in phase 2 were outside of the expected sensitive
range of #6.0 mM. For C9208 (phase 1) and C9209 (phase 2),
single outlier results significantly impacted the CV.
(ii) PFA results. The results for PFA are shown in Table 3.
In phase 1, all results were in the sensitive range for PFA
(IC50 , 400 mM). However, in phase 2, one of seven results for
C9208 and four of seven results for C9209 were in the resistant
range. Likewise, some of the CVs were heavily influenced by
one or two large IC50s (e.g., C9208 and C9209 in phase 2).
Thus, both the IC50s and the CVs were consistently higher for
phase 2 than for phase 1.
An additional finding noted by the participating laboratories
was that plaque counts from wells containing the antiviral drug
at the lowest concentrations frequently exceeded plaque
counts in control wells without the drug when the CMV strain
tested was resistant to the drug tested.
Intralaboratory reproducibility of consensus assay IC50 re-
sults for laboratory strain AD169. Clinical isolates were gen-
TABLE 1. Clinical histories, original IC50s, and mutation analyses of clinical CMV isolates tested
a









C9208 C9208 Pretreatment bone marrow isolate from patient with CLL 1.7 170 wt wt
C9209 C9209 Blood isolate from patient mentioned above with CLL
after 18 months of repeated GCV therapy
7.0 220 V460
F9089 CMV 1 Progression of CMV retinitis on intravenous GCV 8.5 210 V594, S595
K8313 CMV 2 Progression of CMV retinitis on intravenous GCV 8.0 206 I460
MR11979 CMV 3 Developed CMV retinitis after 10 months of oral GCV
prophylaxis; intravenous GCV and PFA failed after 5
months of therapy
.50 870 W603 C412, M802
V15885 CMV 4 Pretreatment isolate from BAL from patient with AIDS 1.2 128.46 wt wt
V379354 CMV 5 Pretreatment blood isolate from patient with CLL 3.42 96.54 wt wt
V917401 CMV 6 Blood isolate from patient with CLL mentioned above
after 469 days of GCV and 98 days of PFA therapy;
patient had persistent viremia and colitis
43.06 179.91 V460 A522, A841
a POL, polymerase gene; CLL, chronic lymphocytic leukemia; wt, wild type; BAL, bronchoalveolar lavage.
b Hybridization assay for C9208, C9209, and CMV 4 to 6 (1, 5, 7); plaque reduction assay for CMV 1 to 3 (3).
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erally tested only once; however, six laboratories tested the
control strain, AD169, from two to four times during phase 2.
Thus, the reproducibility of the IC50 results within each of
these laboratories using the ACTG consensus assay was exam-
ined for AD169 (Table 4).
(i) GCV. AD169 was tested against GCV 19 times in six
laboratories. Fifteen of the 19 results were in the sensitive
range; however, 3 results were in the indeterminate range and
1 was resistant. Two laboratories (A and B) reported one of
three IC50 results above 6.0 mM (9.73 and 78.49 mM), and one
laboratory (K) had two of four results slightly above the sen-
sitive range (6.07 and 6.69 mM).
(ii) PFA. Sixteen IC50 results from six laboratories were
available for the susceptibility of AD169 to PFA. Of these,
15 results ranged from 39 to 184 mM, within the sensitive
range, but 1 result (657.9 mM) was in the resistant range. Notably,
this single resistant result for PFA was from the same test run
and laboratory (B) which found an IC50 for GCV of 78.49 mM for
AD169. These extreme outliers may represent errors in drug
preparation.
With the exception of laboratory B, the CVs within each
laboratory for testing AD169 for the consensus assay were low-
er than the CVs between laboratories (81.6% for GCV and
48.3% for PFA).
TABLE 2. Interlaboratory variability in GCV IC50 determinations by initial (phase 1) and ACTG consensus (phase 2)
plaque reduction assays using plaque-purified viruses
Laboratory
GCV IC50 (mM) for:
AD169a XbaFa C9208b C9209b
Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2
A 5.62 3.17
B 5.49 1.86 86.91 .96 0.66 1.22 79.39 69.09
C 9.04 3.67 25.43 .96 1.63 9.81 NA .96
D 1.33 10.99 48.66 NAc
E 2.34 0.29 14.14 9.30 22.11 1.98 .96 64.24
F 1.02 3.18 5.42 16.03 0.40 0.14 67.68 .96
G 3.87 3.87
H 1.20 1.74 17.86 19.16 96.40 28.25
I 2.70 1.40 37.20 28.69 5.92 4.37 .100 .96
J 2.20 9.57 28.48 43.94 3.60 7.72 .96 6.79
K 9.58 6.07 29.04 26.11 NA
Total no. of assays 11 11 9 8 6 6 6 7
Mean IC50 4.04 4.16 30.56 41.90 5.72 4.21 89.25 65.19
CVd 75.5 81.6 81.2 83.3 145 91.6 14.4 54.7
No. (%) resistant 0 (0) 0 (0) 8 (84) 8 (100) 1 (17) 0 (0) 6 (100) 6 (86)
a Cell-free laboratory strains.
b Cell-associated clinical isolates.
c NA, IC50 could not be determined due to inconsistent results.
d CV determined as (standard deviation/mean) 3 100%.
TABLE 3. Interlaboratory variability in PFA IC50 determinations by initial (phase 1) and ACTG consensus (phase 2)
plaque reduction assays using plaque-purified viruses
Laboratory
PFA IC50 (mM) for:
AD169a XbaFa C9208b C9209b
Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2 Phase 1 Phase 2
A 112.06 86.54
B 59.69 184.22 117.46 244.42 115.51 63.29 116.67 545.94
C 65.69 43.90 116.49 243.09 NAc 437.56 222.42 .1,600
D
E 48.15 43.54 54.96 35.20 56.56 52.53 190.69 690.59
F 50.09 70.81 219.24 140.7 319.91 336.21
G 83.32 77.51
H 53.79 118.87 64.08 87.05 69.13 120.44
I 50.99 76.74 98.30 139.49 229.83 210.65 274.31 445.97
J 35.37 73.19 30.52 119.44 110.13 197.02 150.80 200.1
K 56.51 71.28 28.93 71.49
Total no. of assays 10 10 7 7 5 6 7 7
Mean IC50 61.57 84.66 72.96 134.31 146.25 183.62 191.99 562.75
CVd 35.3 48.3 52.1 61.0 51.4 76.6 45.9 88.4
No. (%) resistant 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 4 (57)
a Cell-free laboratory strains.
b Cell-associated clinical isolates.
c NA, IC50 could not be determined due to inconsistent results.
d CV determined as (standard deviation/mean) 3 100%.
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Use of the ACTG consensus plaque reduction assay for
testing CMV clinical isolates. In phase 2, in addition to the
four plaque-purified strains tested in phase 1 (Tables 2, 3, and
4), six recent CMV clinical isolates (CMV 1 to 6) were distrib-
uted to 12 laboratories and tested using the consensus proto-
col. These isolates were not plaque purified.
(i) GCV. The distribution of results for the GCV IC50 ob-
tained by participating laboratories using the consensus proto-
col is presented in Table 5. The results for clinical isolates
CMV 1 to 6 showed strong agreement in detecting the two
highly resistant isolates, CMV 3 and CMV 6. For two isolates,
CMV 2 and 5, there was consensus for an IC50 of ,6.0. How-
ever, for two isolates, CMV 1 and CMV 4, there was a broad
distribution of results.
(ii) PFA. For PFA (Table 6), all isolates tested had at least
one assay result in the resistant range (.400 mM). However,
only CMV 3 had a majority of test results in the resistant range.
CMV 3 was obtained from a patient for whom PFA and GCV
therapy for CMV retinitis had failed and who had mutations in
both the UL97 and polymerase genes (Table 1). CMV 6 was
also isolated from a patient who failed to respond to PFA, yet
only 3 of 11 test results were in the resistant range. In fact, the
mutations identified in the polymerase gene for CMV 6 have
not been shown to confer PFA resistance.
Impact of challenge dose on consensus assay IC50 results.
To assess the impact of the challenge dose on the results, the
reproducibility and accuracy of the challenge dose was exam-
ined for each of the six clinical isolates, CMV 1 to 6, for each
of the assays shown in Tables 5 and 6. The target of a mean of
40 to 80 plaques per well was achieved in 86 of 138 assays
(62%). The range of mean challenge doses was 22 to 233
plaques per well. Only 2 of 12 laboratories had challenge doses
for all 12 assays within the range; 5 of 12 laboratories had 80%
or more of the assays in the range. The coefficient of variation
among triplicate wells within an assay ranged from 1 to 25.3%;
however, the CV for 80% of the assays was ,15%.
No correlation was found between high or low challenge
dose and a greater incidence of sensitive or resistant IC50
results compared with challenge doses in the target range (data
not shown).
DISCUSSION
Plaque reduction has been considered the gold standard for
antiviral susceptibility testing (13) and is used successfully for
rapidly growing, cell-free clinical isolates of herpes simplex
virus. CMV presents a more difficult problem because isolates
are slow growing and cell associated. Furthermore, plaques are
more difficult to discern in the presence of drugs.
The work presented here represents the first attempt at
developing a consensus plaque reduction assay for CMV drug
susceptibility testing. Such an assay is essential for multicenter
trials and to bring standardization to the field.
What further distinguishes this work is our attempt to do a
plaque reduction assay using cell-associated virus, based on the
method first reported by Stanat et al. (11). Standard CMV
plaque reduction assays described in the past have required
multiple serial passages of a clinical isolate in cell culture to
produce sufficient cell-free virus, followed by virus titration to
determine the challenge dose before the actual susceptibility
testing is performed. In the assay presented here, the virus
challenge dose consists of PFC, estimated by microscopic as-
sessment of the CPE, thus avoiding serial passage and titration.
TABLE 4. Intralaboratory variation in IC50 for laboratory









A 3 4.40 5.76 60.5 3 69.66 83.80 15.5
3.17 86.55
9.73 95.19
B 3 1.86 27.9 156.8 3 184.22 338.67 81.7
78.49 657.39
3.44 173.86




F 2 3.18 2.71 24.5 2 70.81 55.15 40.2
2.24 39.48
I 3 1.40 3.14 48.5 3 76.74 98.42 19.3
4.24 111.87
2.68 106.63




a Number of assays performed in each laboratory.
b CV determined as (standard deviation/mean) 3 100%.
TABLE 5. Frequency distributions of GCV IC50s for recent
clinical isolates using the ACTG consensus protocol
GCV IC50
(mM)
No. of assays with IC50 at each GCV concn
CMV 1a CMV 2 CMV 3 CMV 4 CMV 5 CMV 6
#1.5 2 1 2
.1.5–3.0 3 2
.3.0–6.0 2 2 1 1 7
.6.0–12 2 2 2
.12–24 2 2 2
.24–48 2 2 1 1
.48–96 4 1 1 3
.96 1 10 1 8
Total no. of assays 12 10b 12 12 12 12
Median IC50 22.94 2.97 .96 11.31 4.13 .96
No. (%) resistant 8 (67) 1 (10) 11 (92) 6 (50) 3 (25) 12 (100)
a CMV 1 to 6 were not plaque purified.
b Data not submitted by two laboratories.
TABLE 6. Frequency distributions of PFA IC50s for recent
clinical isolates using the ACTG consensus protocol
PFA IC50
(mM)
No. of assays with IC50 at each PFA concn
CMV 1a CMV 2 CMV 3 CMV 4 CMV 5 CMV 6
,25 2
.25–50 1 2 1
.50–100 1 1 1 3
.100–200 2 2 1 4 6 3
.200–400 4 4 2 4 1 5
.400–800 2 1 2 1
.800–1,600 2 1 2
.1,600 4 1
Total no. of assays 10b 10b 11c 12 12 11c
Median IC50 227.65 200.14 855.85 184.84 117.19 325.18
No. (%) resistant 2 (20) 1 (10) 8 (73) 1 (8) 1 (8) 3 (27)
a CMV 1 to 6 were not plaque purified.
b Data not submitted by two laboratories.
c IC50 could not be determined for one data set due to inconsistent results.
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Such an assay can save weeks to months and provide results in
a more clinically relevant time frame.
In general, strong agreement among laboratories was dem-
onstrated for laboratory strains AD169 and XbaF and for the
plaque-purified clinical isolates C9208 and C9209. However,
plaque purification is a lengthy and time-consuming process
and does not give an accurate representation of the population
of viruses in the patient. Clinical isolates from patients ob-
tained after antiviral treatment frequently consist of a mixture
of viruses with different susceptibilities (6). This may in part
explain the variability in results obtained for CMV strains 1 to
6; these strains were not plaque purified prior to distribution
and were further passaged in each laboratory, which may have
led to some divergence of resistance properties. However,
CMV strains 4 and 5 were pretreatment isolates and were
wild-type viruses by mutation analysis; nevertheless, 25 to 50%
of the laboratories found them resistant to GCV. In contrast,
both CMV strains 3 and 6 were obtained from patients for
whom PFA therapy failed, and both had polymerase muta-
tions; however, only CMV strain 3 was found to be PFA re-
sistant by a majority of participating laboratories, using an IC50
of .400 mM to define resistance. The finding of PFA resis-
tance for C9209 in phase two by four of seven laboratories also
remained unexplained; there was no history of PFA therapy,
no polymerase mutations were detected, and all seven labora-
tories reported results in the sensitive range in phase 1.
The occurrence of outliers, which could sometimes be quite
extreme, was of concern. The frequency of outlier results was
greater for some laboratories but did not appear to be related
to a laboratory’s prior experience with plaque reduction assays.
It should be noted, however, that even laboratories that were
experienced in plaque reduction were not experienced with the
consensus assay. Outlier results also did not correlate with
virus inocula that were higher or lower than the target of 40 to
80 plaques per well. Furthermore, outlier results for AD169
did not correlate with outlier results in concurrently tested
clinical isolates.
The finding of increased plaque counts in wells with low
doses of antiviral drugs was noted especially with resistant
CMV strains. The reasons for this phenomenon are not known
but may include a stimulatory effect on host cells or the virus or
a simple measurement error.
The difficulty many of the laboratories experienced in
achieving a challenge dose in the target range reflects the
difficulty of determining a challenge dose by visual assessment
of the CPE (i.e., PFC). This would most certainly improve with
experience. The reproducibility of plaque counts among trip-
licate wells of an assay, however, was very good and compara-
ble to that achieved with cell-free virus (13).
This collaborative effort represents a first step and highlights
a number of issues for study in the future. Many previous
publications on CMV susceptibility testing have focused on
cell-free virus, on laboratory-passaged virus, or on sensitive
virus strains. We have established a consensus assay, which is
already in use for testing clinical isolates obtained from clinical
trials. Improvements in the assay currently under evaluation
include a reduction in the number of drug concentrations
tested, the use of an overlay medium without agarose, direct
inoculation of CMV-infected cells into overlay medium with-
out adsorption, and counting plaques microscopically in un-
fixed monolayers.
Of note, some clinical isolates may exhibit variability in an-
tiviral susceptibility results, and these isolates may represent
mixed populations. Further testing of these isolates by other
methods, such as nucleic acid sequence analysis, may be nec-
essary to explain this variability.
In contrast to the ACTG assay for antiviral susceptibility for
human immunodeficiency virus type 1 in peripheral blood
mononuclear cells, the ACTG standardized consensus meth-
odology for CMV presented in this report did not result in a
significant decrease in the CV. It is clear from this study that
any laboratory wanting to establish a CMV plaque reduction
assay for cell-associated CMV isolates will need to devote
substantial effort over an extended period of time to develop-
ing and documenting the reproducibility of results. Establish-
ing sharply delineated boundaries between sensitive and resis-
tant strains may be difficult. Rather, testing paired pre- and
posttreatment isolates to detect trends toward resistance may
give more meaningful results.
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